Real-world evidence vendors help manufacturers answer clinical, regulatory, access, and commercial questions using data generated outside traditional randomized trials. The work can include claims, EHR, labs, registries, genomic data, specialty pharmacy records, patient-reported outcomes, and linked longitudinal datasets.
The buyer challenge is to separate data access from evidence generation. A large dataset is useful only when the vendor can design a credible study, control bias, interpret the clinical context, and translate findings into a regulatory, payer, medical, or launch decision.
Core Services
- RWE study design and execution: Observational studies, comparative effectiveness, natural-history studies, pragmatic trials, external controls, and post-market evidence programs
- Claims, EHR, and linked-data analytics: Patient journey analysis, treatment sequencing, burden-of-disease studies, site and provider mapping, and outcomes measurement
- Disease registries and longitudinal cohorts: Registry design, patient follow-up, data capture, governance, and evidence generation for rare disease, oncology, specialty, and post-approval commitments
- HEOR and value evidence: Budget impact, cost-effectiveness, quality-of-life, resource-use, and value-dossier analytics for payer, HTA, and CMS-facing evidence needs
- Regulatory-grade evidence support: Protocols, statistical analysis plans, audit-ready methods, sensitivity analyses, and evidence packages for supplemental or post-market use cases
- Trial and launch enablement: Feasibility analysis, external control arm support, patient finding, site selection, and medical/commercial insight generation
Competitive Landscape
The landscape splits between data-platform operators, disease-depth specialists, and evidence-service firms. Komodo Health, Clarify Health, HealthVerity, TriNetX, Inovalon, and IQVIA compete around broad patient-journey, provider, payer, and commercial analytics use cases. Flatiron Health and ConcertAI are more specialized oncology evidence platforms, with first-party or curated clinical depth that is difficult for general claims vendors to replicate. Certara, OPEN Health, Avalere Health, Xcenda, Guidehouse, Red Nucleus, Omega Healthcare, and similar firms bring HEOR, evidence strategy, study execution, or data-curation capacity.
Competitive selection should begin with the endpoint. Oncology biomarker work, rare-disease natural history, payer budget impact, trial feasibility, and post-market safety surveillance may each point to a different vendor type even when all are marketed as “RWE.”
Buyer Context
RWE is most valuable for specialty launches, accelerated or conditional evidence obligations, payer value dossiers, label or guideline support, post-market surveillance, competitive differentiation, and trial optimization. Emerging biotechs often need a partner that can translate evidence into market access and medical strategy; larger manufacturers may need deeper data assets, repeatable methods, or therapeutic-area specialists to fill gaps in internal analytics teams.
What to Look for When Evaluating RWE Vendors
- Fit-for-purpose data: Claims, EHR, oncology abstraction, labs, genomics, pharmacy, and registry data answer different questions. Ask whether the dataset captures the patients, endpoints, and follow-up window you need.
- Methodological rigor: Evaluate protocol discipline, biostatistics, missing-data handling, confounding control, linkage methodology, auditability, and sensitivity-analysis standards.
- Therapeutic-area depth: Oncology, rare disease, immunology, cardiometabolic, and specialty pharmacy use cases require different clinical abstraction and endpoint expertise.
- Regulatory and payer translation: Determine whether the vendor can produce evidence that fits the intended use, such as post-approval commitments, value dossiers, HTA submissions, label support, or payer objections.
- Operating model clarity: Decide whether you are buying a data subscription, a custom study, an embedded analytics partner, or a strategy-plus-evidence engagement.
Common Pitfalls
- Treating RWE as post-hoc proof: Retrospective analysis can inform strategy, but decision-grade evidence should be designed around a specific regulatory, payer, medical, or trial question.
- Buying scale without clinical context: Broad claims coverage may not capture stage, biomarkers, disease severity, response, progression, or treatment rationale.
- Ignoring bias and linkage risk: Selection bias, missing data, variable definitions, and weak patient matching can undermine an otherwise attractive dataset.
- Separating RWE from the decision owner: Evidence work loses value when HEOR, regulatory, medical affairs, market access, and clinical development are not aligned on the use case.
